SARS Mosaic S(C)
Description
C-terminal t section of the Spike protein 1051-1076, 1121-1154, 1162-1190 amino acids immunodominant regions.
Product Specs
SARS Mosaic protein is Immunoreactive with sera of SARS-infected individuals.
Product Science Overview
The SARS-Associated Coronavirus Spike Mosaic S© Recombinant is a significant advancement in the study of coronaviruses, particularly the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the COVID-19 pandemic. This recombinant protein is designed to mimic the spike (S) protein of the virus, which plays a crucial role in the virus’s ability to infect host cells.
The spike protein of SARS-CoV-2 is a large glycoprotein that protrudes from the viral surface and is responsible for binding to the host cell receptor, angiotensin-converting enzyme 2 (ACE2). The spike protein is composed of two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which directly interacts with ACE2, while the S2 subunit is involved in the fusion of the viral and host cell membranes .
The Mosaic S© Recombinant is engineered to include multiple epitopes from different variants of the spike protein. This design aims to enhance the immune response by presenting a broader range of viral antigens to the immune system. By incorporating epitopes from various strains, the Mosaic S© Recombinant can potentially provide broader protection against different variants of the virus .
One of the primary applications of the SARS-Associated Coronavirus Spike Mosaic S© Recombinant is in vaccine development. Traditional vaccines often target a single variant of the virus, which can limit their effectiveness as the virus mutates. The Mosaic S© Recombinant, however, offers a more versatile approach by targeting multiple variants simultaneously. This can lead to the development of vaccines that are more effective against a wider range of SARS-CoV-2 variants .
Research on the Mosaic S© Recombinant is ongoing, with several studies focusing on its efficacy and safety. Early results have shown promise, with the recombinant protein eliciting strong immune responses in preclinical trials. Clinical trials are being conducted to further evaluate its potential as a vaccine candidate .
